Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 38 of 38 entries
View as:

A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin

Phase: N/A Priority: Normal
NCT ID: NCT00268853 Org: User:
Start: 11/30/05 End: 05/31/12 Due: 05/31/13

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Phase: N/A Priority: Normal
NCT ID: NCT00577161 Org: User:
Start: 09/30/07 End: 07/31/12 Due: 07/31/13

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Phase: N/A Priority: Normal
NCT ID: NCT05552183 Org: User:
Start: 12/12/22 End: 06/10/24 Due: 06/10/25

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00017069 Org: User:
Start: 02/28/01 End: 01/31/05 Due: 01/31/06

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00060671 Org: User:
Start: 01/31/05 End: 01/31/06 Due: 01/31/07

Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02765724 Org: User:
Start: 01/31/15 End: 06/30/15 Due: 06/30/16

To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02807051 Org: User:
Start: 09/30/14 End: 10/31/14 Due: 10/31/15

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

Phase: N/A Priority: Normal
NCT ID: NCT00576225 Org: User:
Start: 09/30/07 End: 04/05/10 Due: 04/05/11

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01773187 Org: User:
Start: 01/31/13 End: 04/30/16 Due: 04/30/17

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00551239 Org: User:
Start: 08/31/07 End: - Due: -

Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib

Phase: N/A Priority: Normal
NCT ID: NCT02803762 Org: User:
Start: 07/31/14 End: 10/31/14 Due: 10/31/15

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT00106600 Org: User:
Start: 03/31/05 End: 03/31/07 Due: 03/31/08

To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02807207 Org: User:
Start: 10/31/14 End: 12/31/14 Due: 12/31/15